Amalgamated Financial’s ARS Pharmaceuticals SPRY Stock Holding History

Amalgamated Financial’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$9K	Buy	+2,469	New	+$10.7K	﹤0.01%	2915

Other funds holding SPRY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Financial's SPRY Position: Q1 2022 in Review

Amalgamated Financial opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2022: 2,469 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #2915 among its holdings.

70 funds tracked by Wall St. Rank hold SPRY as of Q1 2022.

Amalgamated Financial held 2,469 shares of ARS Pharmaceuticals worth $9K as of Q1 2022.
ARS Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
ARS Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2915 holding.
70 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.